Efficiency of a New Combined Laser Therapy in Patients With Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency

Sergey Vladimirovich Moskvin¹, Aleksandr Vladimirovich Geynitz², Evgeniy Valer’yevich Askhadulin³*

¹State Scientific Center of Laser Medicine, Moscow, Russia
²Reaviz Moscow Medical Institute, Moscow, Russia
³Tula E.G. Lasarev Municipal Clinical Hospital №2, Russia

Abstract

Introduction: Treating patients with trophic ulcers (TU) of venous etiology (VE) is a complicated socio-medical and economic problem. One of the ways to increase treatment efficiency can be a complex therapy, including combined laser action.

Methods: The objective of this study was a comparative evaluation of the efficiency of traditional treatment methods in patients with chronic venous diseases of C6 class, and combined laser therapy (LT) according to a new method by LASMIK® device. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone (pulsed mode, light pulse duration of 100-130 ns, wavelength 635 nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8 cm², at a distance of up to 7 cm, pulsed power 40 W). Intravenous laser blood illumination (ILBI) was conducted in continuous mode with a wavelength of 365-405 nm (UV-spectrum) and 520-525 nm (green spectrum) alternately, during 12 daily sessions, according to a special scheme.

Results: The new method reduces time periods for wound surface cleansing from purulonecrotic masses, stimulates proliferation and epithelialization processes by 2-2.7 times, compared with the conventional method.

Conclusion: The high efficiency of a new combined LT has been demonstrated in the treatment of TU of VE in combination with traditional methods of patients’ medical treatment.

Keywords: Trophic ulcer of venous etiology; Low level laser therapy; Venous Insufficiencies; Ulcer.

Introduction

Treated patients with trophic ulcer (TU) in lower extremities with venous etiology (VE) is a complicated socio-medical and economic problem. Prevalence of 'venous' TU in the adult working-aged population of the Russian Federation is 1%-2%, it occurs more often in female than in male, in 0.3% of TU of VE cases, the healing process takes a very long time with repeated recurrence.¹⁻⁴ Despite the advances of modern medicine, in particular, phlebology, the TU incidence rate has remained consistent over the past 20 years. There is a clear tendency towards the rejuvenation of this contingent of patients; it increases up to 4%-5% with age (in patients over 65 years old), and the radical elimination of the disease can be achieved only in every tenth patient.¹ The problem is exacerbated by the presence of concomitant pathology.⁵

The main factors affecting patients’ quality of life with venous TU include a pain syndrome (80% of patients), resulting in insomnia (74% of patients), significant everyday inconveniences associated with hygiene procedures (90% of patients) and a selection of comfortable shoes (78%). Under the influence of these factors, psychological problems occur in the majority of patients. It was found that 26% of patients suffering from TU experience overwhelming fear to hurt their legs when playing games with children, 34% of them fear pets, another 27% cease communicating with their friends and colleagues. Only 3% TU patients have active sex life, most of them retaining normal potency. This has a negative impact on family relations and is a cause of divorce in 47% of cases.⁶

The cost of treating venous TU can vary within wide limits and depends on the technology used. In the countries of the European community, the closure of one TU as an outpatient procedure costs 800-1500 euros, and supporting anti-relapse treatment makes 100-150 euros per month. In the United States, for closure of venous TU patients, resulting in insomnia (74% of patients), significant everyday inconveniences associated with hygiene procedures (90% of patients) and a selection of comfortable shoes (78%). Under the influence of these factors, psychological problems occur in the majority of patients. It was found that 26% of patients suffering from TU experience overwhelming fear to hurt their legs when playing games with children, 34% of them fear pets, another 27% cease communicating with their friends and colleagues. Only 3% TU patients have active sex life, most of them retaining normal potency. This has a negative impact on family relations and is a cause of divorce in 47% of cases.⁶

The cost of treating venous TU can vary within wide limits and depends on the technology used. In the countries of the European community, the closure of one TU as an outpatient procedure costs 800-1500 euros, and supporting anti-relapse treatment makes 100-150 euros per month. In the United States, for closure of venous TU patients, resulting in insomnia (74% of patients), significant everyday inconveniences associated with hygiene procedures (90% of patients) and a selection of comfortable shoes (78%). Under the influence of these factors, psychological problems occur in the majority of patients. It was found that 26% of patients suffering from TU experience overwhelming fear to hurt their legs when playing games with children, 34% of them fear pets, another 27% cease communicating with their friends and colleagues. Only 3% TU patients have active sex life, most of them retaining normal potency. This has a negative impact on family relations and is a cause of divorce in 47% of cases.⁶

The cost of treating venous TU can vary within wide limits and depends on the technology used. In the countries of the European community, the closure of one TU as an outpatient procedure costs 800-1500 euros, and supporting anti-relapse treatment makes 100-150 euros per month. In the United States, for closure of venous TU
Methods

This study was performed as a clinical trial (Clinical Trials.gov; Identifier: NCT03104985). During a longitudinal study, a group of patients was followed up in the period of complete or partial recovery. The analysis of the results of outpatient examination and treatment of 68 patients with venous TU, from 2013 to 2015, observed in the City Polyclinic of “Tula Municipal Clinical Hospital №2” was carried out.

The group of patient consisted of 50 (73.5%) women and 18 (26.5%) men. Patients’ age varied from 39 to 78 years old. A mean age was 57.2 ± 0.5 years. Patients were examined as follows: general clinical methods of investigation (complete blood count, clinical urine analysis, biochemical blood assay, including glucose test, blood coagulation system test, culture and sensitivity tests of the ulcer defect surface) and instrumental investigations (ultrasonic Doppler examination [USDG], the measurement of the TU size with the calibration ruler).

Duration of the disease was above 5 years in 27 patients (39.7%) and less than 5 years in 41 patients (60.3%). There were 47 (69.1%) patients with varicose disease and 21 (30.4%) patients with post-thrombophlebitic disease.

International classification of lower extremity chronic venous disorders (CEAP) was used as a clinical classification of chronic venous insufficiency (CVI). In our survey, all patients had CVI Stage 6 (56) in compliance with CEAP.

TU were localized over the medial ankle in 40 (58.8%) patients, over the lateral malleolus in 18 (26.5%) patients, in the combination of contralateral surfaces in 10 (14.7%). The disease recurrence was identified in 39 (57.3%) patients when they visited the clinic. Ulcer defects sized below 5 cm² in 32 (47%) patients; from 5 to 10 cm² in 28 (41.2%) and from 10 to 25 cm² in 8 (11.8%). Depending on the applied treatment method, patients were divided into 2 groups (Table 1).

Group 1 was represented by 34 (50%) patients who underwent conventional therapy. It included:

- An elastic compression of lower extremities (elastic bandages or compression hosiery of class 2).
- Pharmacotherapy: to improve venous tonus the following drugs were used: Anavenol, Aescusan, Glyvenol; lymphatic drainage function was improved using drugs of the benzopyrone group, including Troxevasin and Venoruton. In order to eliminate microcirculation disturbances and regulate hemorheology, Trental, aspirin and Ticlid (ticlopidine) were used.
- Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs were used to stop inflammation. Antibiotic therapy of ulcer defect was administered in accordance with the sensitivity after determining microflora by culture inoculation
- Topical treatment was administered according to the general surgical rules: in the presence of purulent discharge (phase I of the wound healing process),...
bandaging with antiseptic solutions (1% iodopiron solution, 0.1% chlorhexidine solution) and hydrophilic ointments (levosin, levomecol) were applied. In phases II and III, after ulcer cleansing, the treatment was aimed toward stimulating the granulation and marginal epithelization development. For this purpose, we used the preparations based on hyaluronic acid (Curiozin).

To carry out LT, the physiotherapeutic device LASMIK® was used (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015). External exposure and ILBI were included in a daily complex of standard therapy. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration of 100-130 ns, with wavelength 635 nm, by a matrix emitter consisting of 8 laser diodes with a surface area of 8 cm², at a distance of up to 7 cm, with pulsed power of 40 W. ILBI was conducted in continuous mode with wavelength between 365-405 nm (UV-spectrum) and 520-525 nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:

- Session 1 – 365-405 nm, power 1-2 mW, exposure 2 minutes;
- Session 2 – 520-525 nm, power 1-2 mW, exposure 5 minutes;
- Session 3 – 365-405 nm, power 1-2 mW, exposure 2 minutes;
- Session 4 – 520-525 nm, power 1-2 mW, exposure 5 minutes;
- Session 5 – 365-405 nm, power 1-2 mW, exposure 2 minutes;
- Session 6 – 520-525 nm, power 1-2 mW, exposure 5 minutes;
- Session 7 – 365-405 nm, power 1-2 mW, exposure 2 minutes;
- Session 8 – 520-525 nm, power 1-2 mW, exposure 5 minutes;
- Session 9 – 365-405 nm, power 1-2 mW, exposure 2 minutes;
- Session 10 – 520-525 nm, power 1-2 mW, exposure 5 minutes;
- Session 11 – 365-405 nm, power 1-2 mW, exposure 2 minutes;
- Session 12 – 520-525 nm, power 1-2mW, exposure 5 minutes.

Patients in the control group were representative by age, sex, prevalence of lesions and the presence of comorbidities. Patients were distributed by random sampling: simulation of laser exposure was not performed.

**Results and Discussion**

Evaluation of clinical treatment results showed that a slight dynamics of changes in the clinical picture was identified in patients with venous TU of group 1, who received only conventional treatment. After 14 days of treatment, edema of shank reduced only in 9 (26.5%) patients, and the pain stopped only in 7 (20.6%) patients.

In group 2, where in addition to conventional therapy, LLLT was performed according to the combined procedure, in contrast to the patients’ group 1, who received only conventional treatment, pain reduction in the lower extremities and even much faster decrease in inflammatory phenomena in the TU area were noted in 5-7 days. Thus, surrounding tissue hyperemia persisted for 3-3.5 days, and infiltration around the edges of TUs remained for 4-4.5 days. Key indicators of wound healing process dynamics in patients with venous TU are given in Table 2.

As follows from the table data, in the group treated by conventional method, average TU cleansing time was 9.8 ± 0.2 days, generation of granulation tissue was identified in 10.3 ± 0.8 days and a healing (50% epithelialization) in 28.1 ± 1.4 days.

In the second group, the average time of cleansing from purulo-necrotic masses, granulation occurrence and ulcer epithelialization took, respectively: 6.4 ± 0.4, 7.1 ± 0.6 and 12.8 ± 1.6 days.

Compared to the patients of the first group, application of the developed technique for treating TU in patients with CVI of lower extremities promoted time reduction in ulcer cleansing by 1.5, granulation occurrence by 1.4 times, wound healing (50% epithelialization) by 2.2 times. Conservaive treatment was applied for patients with venous TU either as a preparation for surgical interventions aimed at correcting venous circulation of lower extremities, or as the main therapy, when there were contraindications to surgery or patients’ categorical refusal of the operation.

The treatment results were evaluated after 6 months. Clinical dynamics were characterized by a more pronounced improvement in overall health, decrease in feeling of ‘tiredness’ in legs, reduced edema of shanks and feet in patients with venous TU in 6 months after treatment in group 2, which included external exposure with wavelength of 635 nm and ILBI with wavelength of 365-405 nm (UV-spectrum) and 520-525 nm (green spectrum) alternately.

### Table 1. Distribution of Patients Depending on the Treatment Method

<table>
<thead>
<tr>
<th>No.</th>
<th>Treatment Methods</th>
<th>Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Conventional treatment</td>
<td>34</td>
</tr>
<tr>
<td>2</td>
<td>Conventional treatment + combined LLLT, including external exposure with 635 nm wavelength + ILBI with wavelength alternately, according to the scheme</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td><strong>68</strong></td>
</tr>
</tbody>
</table>

**Abs.**
spectrum). The clinical picture of the first group corresponded to that prior to the therapy course.

In our opinion, the results of healing venous TU in groups are indicative. Thus, among patients receiving only conventional therapy, TU healing in 6 months was identified in 11 (32.3%) patients. Ulcer epithelialization occurred in 28 (82.3%) patients receiving conventional therapy and LT with external exposure and ILBI with wavelength of 365-405 nm (UV A-spectrum) and 520-525 nm (green spectrum).

Thus, it is shown that the proposed method allows to carry out more effective treatment of patients with TU of VE, reduce time of healing, and to stimulate quite pronounced and persistent adaptive physiological response, that prevents TU relapse development.

**Conclusion**

The new method of treating patients with TUs of VE using low level laser irradiation contributes to reduce time periods for wound surface cleansing from purulo-necrotic masses, stimulates proliferation and epithelialization processes by 2-2.7 times, compared with the conventional method, which allows improvement of treatment results for this group of patients, reducing time of ulcer healing, lowering the incidence of incapacitation and social adaptation costs.

**Conflict of Interests**

The authors declare no conflict of interest, financial or other exists.

**Ethical Considerations**

This study has been approved by ethical committee of Tula E.G. Lasarev Municipal Clinical Hospital №2, Russia.

**References**

3. Tolstykh PI, Tamrazova OB, Pavlenko VV, Kuleshov YI, Tolstykh MP. Dlitel’noe ne zazhivayuschchiye rany i yazvy (patogeneza, klinika, lecheniye) (Long-term healing wounds and ulcers [pathogenesis, clinic, treatment]). Moscow: Dipak; 2009. [Russian].
17. Myshentsev PN, Zhukov BN, Katorkin SE, Yarovenko GV. The role of computer tomodraphy in the evaluation of the lower extremities lymphedema stage. Novosti Khirurgii. 2011;19(5):74-77. [Russian].

**Table 2. Key Indicators of Wound Healing Progression in the Surveyed Groups**

<table>
<thead>
<tr>
<th>Patient Groups</th>
<th>Average Time (in days)</th>
<th>Wound Healing (50% Epithelialization) in 6 Months, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wound Surface Cleansing</td>
<td>Granulation Occurrence</td>
<td>Epithelialization) in 6 Months, No. (%)</td>
</tr>
<tr>
<td>Group 1 (n = 34)</td>
<td>9.8 ± 0.2</td>
<td>10.3 ± 0.8</td>
</tr>
<tr>
<td>Group 2 (n = 34)</td>
<td>6.4 ± 0.4*</td>
<td>7.1 ± 0.6*</td>
</tr>
</tbody>
</table>

*Statistically significant difference of groups 1 and 2 (P<0.05).